Vessel size imaging (VSI) by robust magnetic resonance (MR) Relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy

Molecular Imaging

Volumn 12, Issue 7, 2013, Pages

  Persigehl, Thorsten ^a   Ring, Janine ^b   Budny, Tymoteusz ^b   Hahnenkamp, Anke ^b   Stoeppeler, Sandra ^b   Schwartz, Lawrence H ^b   Spiegel, Hans Ullrich ^b   Heindel, Walter ^b   Remmele, Stefanie ^b   Bremer, Christoph ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INTRAVITAL MICROSCOPY; NON-INVASIVE ASSESSMENTS; NONINVASIVE ESTIMATION; SOLID TUMORS; SUPERPARAMAGNETIC PARTICLES; VESSEL MORPHOLOGY;

BIOLOGICAL MATERIALS; MAMMALS; NONINVASIVE MEDICAL PROCEDURES; TUMORS;

MAGNETIC RESONANCE;

ANGIOGENESIS INHIBITOR; DEXTRAN; FERUMOXTRAN-10; INDOLE DERIVATIVE; MAGNETITE NANOPARTICLE; PYRROLE DERIVATIVE; SUNITINIB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DEVICES; EVALUATION STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MOUSE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PROCEDURES; RANDOMIZATION; TUMOR CELL LINE; VASCULARIZATION; ARTICLE; EQUIPMENT; EXPERIMENTAL NEOPLASM; METHODOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DEXTRANS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, NUDE; MICROSCOPY; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RANDOM ALLOCATION;

EID: 84885140219     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2013.00059     Document Type: Article

References (50)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6, doi:10.1056/NEJM197108122850711.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57, doi:10.1038/35025220.
3. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87, doi:10.1093/ jnci/84.24.1875.
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62, doi:10.1126/ science.1104819.
5. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8, doi:10.1056/NEJM199101033240101.
6. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005;19(4 Suppl 3):7-16.
7. Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005;104:2323-33, doi:10.1002/cncr.21453.
8. Berz D, Wanebo H. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. J Surg Oncol 2011;103: 574-86, doi:10.1002/jso.21776.
9. Dennie J, Mandeville JB, Boxerman JL, et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-9, doi:10.1002/mrm.1910400602.
10. Troprès I, Grimault S, Vaeth A, et al. Vessel size imaging. Magn Reson Med 2011;45:397-408, doi:10.1002/1522-2594(200103)45:3 〈.397::AID-MRM1052〉.3.0.CO;2-3.
11. Kiselev VG, Strecker R, Ziyeh S, et al. Vessel size imaging in humans. Magn Reson Med 2005;53:553-63, doi:10.1002/mrm.20383.
12. Farrar CT, Kamoun WS, Ley CD, et al. In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model. Neuro-Oncology 2010;12:341-50.
13. Valable S, Lemasson B, Farion R, et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 2008;21:1043-56, doi:10.1002/nbm.1278.
14. Lemasson B, Valable S, Farion R, et al. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med 2012;69:18-26, doi:10.1002/mrm. 24218.
15. Howe FA, McPhail LD, Griffiths JR, et al. Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. Int J Radiat Oncol Biol Phys 2008;71:1470-6, doi:10.1016/j.ijrobp. 2008.04.027.
16. Ullrich RT, Jikeli JF, Diedenhofen M, et al. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS One 2011;6: e19592, doi:10.1371/journal.pone. 0019592.
17. Bauerle T, Merz M, Komljenovic D, et al. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res 2010;16:3215-25, doi:10.1158/1078-0432.CCR-09-2932.
18. Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer 2011;47:277-86, doi:10.1016/j.ejca. 2010.08.019.
19. Wade TP, Kozlowski P. Longitudinal studies of angiogenesis in hormone-dependent Shionogi tumors. Neoplasia 2007;9:563-8, doi:10.1593/neo. 07313.
20. Lemasson B, Christen T, Tizon X, et al. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR Biomed 2011;24:473-82, doi: 10.1002/nbm.1611.
21. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 2011;1(1):35-40.
22. Persigehl T, Wall A, Kellert J, et al. Tumor blood volume determination by using susceptibility-corrected deltaR2&z.ast; multiecho MR. Radiology 2010;255:781-9, doi:10.1148/radiol.10090832.
23. Bremer C, Mustafa M, Bogdanov A Jr, et al. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens: a study in mice. Radiology 2003;226:214-20, doi:10.1148/radiol.2261012140.
24. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010;21 Suppl 1:S3-11.
25. Remmele S, Ring J, Senegas J, et al. Concurrent MR blood volume and vessel size estimation in tumors by robust and simultaneous deltaR(2) and deltaR(2)&z.ast; quantification. Magn Reson Med 2011; 66:144-53, doi:10.1002/mrm.22810.
26. Zhu H, Melder RJ, Baxter LT, Jain RK. Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res 1996;56:3771-81.
27. Heemskerk AM, Drost MR, van Bochove GS, et al. DTI-based assessment of ischemia-reperfusion in mouse skeletal muscle. Magn Reson Med 2006;56:272-81, doi:10.1002/mrm.20953.
28. Budny T, Palmes D, Stratmann U, et al. Morphologic features in the regenerating liver - a comparative intravital, lightmicroscopical and ultrastructural analysis with focus on hepatic stellate cells. Virchows Arch 2007;451:781-91, doi:10.1007/s00428-007-0472-x.
29. Hricak H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology 2011;259:633-40, doi:10.1148/radiol.11110252.
30. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-42, doi:10.1002/nbm.731.
31. Daldrup HE, Shames DM, Husseini W, et al. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 1998;40:537-43, doi:10.1002/mrm.1910400406.
32. Pannetier N, Lemasson B, Christen T, et al. Vessel size index measurements in a rat model of glioma: comparison of the dynamic (Gd) and steady-state (iron-oxide) susceptibility contrast MRI approaches. NMR Biomed 2012;25:218-26, doi:10.1002/nbm.1734.
33. Flexman JA, Yung A, Yapp DT, et al. Assessment of vessel size by MRI in an orthotopic model of human pancreatic cancer. Conf Proc IEEE Eng Med Biol Soc 2008;2008:851-4.
34. http://clinicaltrials.gov/ct2/results?term5NCT+00103038& Search5Search.
35. Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009;29:1125-33, doi:10.1002/jmri.21710.
36. Wagner M, Wagner S, Schnorr J, et al. Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging 2011;34:816-23, doi:10.1002/ jmri.22683.
37. Tombach B, Reimer P, Bremer C, et al. First pass- and equilibrium- MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study. NMR Biomed 2004;3:500-6, doi:10.1002/nbm.906.
38. Troprès I, Lamalle L, Farion R, et al. Vessel size imaging using low intravascular contrast agent concentrations. MAGMA 2004;17: 313-6, doi:10.1007/s10334-004-0067-3.
39. Douma K, Oostendorp M, Slaaf DW, et al. Evaluation of magnetic resonance vessel size imaging by two-photon laser scanning microscopy. Magn Reson Med 2010;63:930-9, doi:10.1002/ mrm.22248.
40. Kiselev V. Spin echo amplitude in biological tissue with implications for vessel size imaging. Joint Annual Meeting of the ISMRM-ESMRMB; 2010 May 1-7; Stockholm. 2010. p. 1792.
41. Lemasson B, Valable S, Farion R, et al. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology Magn Reson Med 2013;69:18-26, doi:10.1002/mrm. 24218.
42. Tropres I, Lamalle L, Peoc'h M, et al. In vivo assessment of tumoral angiogenesis. Magn Reson Med 2004;51:533-41, doi:10.1002/ mrm.20017.
43. Beaumont M, Lemasson B, Farion R, et al. Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrastenhanced MRI. J Cereb Blood Flow Metab 2009;29:1714-26, doi:10.1038/jcbfm.2009.86.
44. Ungersma SE, Pacheco G, Ho C, et al. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med 2010;63:1637-47, doi:10.1002/mrm.22442.
45. Zama A, Tamura M, Inoue HK. Three-dimensional observations on microvascular growth in rat glioma using a vascular casting method. J Cancer Res Clin Oncol 1991;117:396-402, doi:10.1007/ BF01612757.
46. Tombach B, Reimer P, Mahler M, et al. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad Radiol 2002;9 Suppl 2:S425-7, doi:10.1016/S1076-6332(03)80251-9.
47. Reimer P, Bremer C, Allkemper T, et al. Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebocontrolled clinical phase i study. Radiology 2004;231:474-81, doi:10.1148/radiol.2312021251.
48. Ross RW, Zietman AL, Xie W, et al. Lymphotropic nanoparticleenhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009;33:301-5, doi:10.1016/ j.clinimag.2009.01.013.
49. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009;53:2039-50, doi:10.1016/j.jacc.2009.03. 018.
50. Vellinga MM, Vrenken H, Hulst HE, et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J Magn Reson Imaging 2009;29:774-9, doi:10.1002/jmri.21678.